Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : THE WHITE HOUSE -- Ignore unavailable to you. Want to Upgrade?

To: d[-_-]b who wrote (19278)	4/14/2008 2:29:24 PM
From: Gersh Avery	Read Replies (1) \| Respond to of 25737

That was with a combination of two canabinoids, THC and CBD. The company must have had some indication there was a hope. Otherwise there wouldn't have been the attempt. Marijuana, in it's natural has 76 canabinoids discovered so far. Oh wait .. I see you searched marijuana and diabetes. Try Sativex and diabetes.

To: d[-_-]b who wrote (19278)	4/14/2008 2:42:01 PM
From: Gersh Avery	Respond to of 25737

OK .. here you go: Highly Promising Results for New GW Cannabinoid Treatments for Diabetes and Related Metabolic Disorders 22/01/2008 Preparations underway for commencement of Phase II trials in 2008 Porton Down, UK, 22 January 2008: GW Pharmaceuticals plc (AIM: GWP) announces that it has generated highly promising results in both pre-clinical pharmacology studies and a Phase I trial of a new potential cannabinoid treatment for type 2 diabetes and related metabolic disorders. This research is part of a programme being conducted by GW to evaluate selected cannabinoids in a range of therapeutic areas. GW’s initial cannabinoid target in this field, delta-9-tetrahydrocannabivarin (THCV), has successfully completed extensive pre-clinical pharmacology studies and its first Phase I clinical trial. The pre-clinical studies have yielded highly promising findings. Recent results in several models of diabetes show desirable effects on plasma insulin, leptin and adiponectin levels, hormones of particular relevance to the development and treatment of diabetes, especially in obese individuals. In addition, we have seen a reduction in total cholesterol with an increase in the proportion of HDL (good) cholesterol. The recently completed Phase I trial was a randomised, double blind, placebo controlled, dose escalation, safety and tolerability study of single doses of THCV in twelve healthy volunteer subjects. This trial showed that the study medication was well tolerated at target therapeutic doses and demonstrated a satisfactory safety profile. Following on from this first study, GW is now preparing for a Phase IIa multiple dose study in type 2 diabetic patients in 2008. These recent results add to previous findings showing effects on body weight, body fat content, energy expenditure, food intake, and other obesity-related parameters. Dr Stephen Wright, R&D Director of GW, said, “These new results confirm that GW’s proprietary plant-based cannabinoids have significant potential as treatments in this important branch of therapeutics. We are now ready to build upon the pre-clinical data, as well as the Phase I trial results, by entering Phase II proof of principle studies during 2008.” Dr Geoffrey Guy, Chairman, said, ”This exciting research programme is a further example of the range of potential for GW’s cannabinoids as new medicines. We believe that our research in the field of metabolic disorders represents a significant opportunity for GW and that it has the potential to be an important new area for future collaboration with partners.” production.investis.com